Cell/Gene Tx channel feed

FDA ap­proves Ver­tex and CRISPR's Cas­gevy as first CRISPR-edit­ed ther­a­py for be­ta-tha­lassemia

Last year
FDA+

Ex­clu­sive: Au­toim­mune CAR-T biotech Kyver­na Ther­a­peu­tics is con­sid­er­ing an IPO next month

Last year
Financing
Startups

FDA de­vel­ops pi­lot to har­mo­nize in­ter­na­tion­al gene ther­a­py reg­u­la­tions

Last year
Pharma
FDA+

Blue­bird is still look­ing for more fi­nanc­ing as it brings sick­le cell ther­a­py to mar­ket: #JPM24

Last year
Financing

FDA's CBER chief hints at ex­pand­ing Sarep­ta's gene ther­a­py la­bel, sends stock up 25%

Last year
FDA+

Jen­nifer Doud­na, Fy­o­dor Urnov want to stream­line gene edit­ing stud­ies with Dana­her's help

Last year
R&D

Ather­sys files for Chap­ter 11 bank­rupt­cy, sells every­thing to part­ner Healios

Last year
Deals

Ul­tragenyx nears $50M Se­ries A for its Alzheimer's gene ther­a­py spin­out: #JPM24

Last year
Financing

FDA's Pe­ter Marks says some sec­ondary can­cer cas­es af­ter CAR-T ther­a­py may be 'causal,' but ben­e­fits still out­weigh risks: #JPM24

Last year
FDA+

New David Liu study de­tails virus-like de­liv­ery sys­tem for prime edit­ing

Last year
Discovery

Ver­tex paus­es di­a­betes islet cell ther­a­py study af­ter two pa­tient deaths it says are un­re­lat­ed to drug

Last year
R&D

Gene edit­ing com­pa­ny Metageno­mi sub­mits IPO pa­per­work in third planned biotech list­ing of 2024

Last year
Financing
Startups

Al­lo­gene Ther­a­peu­tics plans re­struc­tur­ing as it swaps out PhII CAR-T tri­al plans to leapfrog ri­vals

Last year
R&D

Blue­bird snags more out­comes-based cov­er­age for its $3M+ sick­le cell gene ther­a­py

Last year

Ab­b­Vie taps Umo­ja for new in vi­vo CAR-T deal

Last year
Deals

Backed by CRISPR pi­o­neer Feng Zhang, epi­ge­net­ics biotech Moon­walk de­buts with $57M

Last year
Startups

Bay­er and AskBio re­veal ear­ly safe­ty da­ta for Parkin­son's gene ther­a­py, plot PhII study

Last year
R&D

Pfiz­er gene ther­a­py gets he­mo­phil­ia B ap­proval in Cana­da, set­ting stage for CSL ri­val­ry

Last year
Pharma
FDA+

No­var­tis dou­bles down on neu­ro­log­ic gene ther­a­py work with Voy­ager

Last year
Deals
Pharma

Ex­clu­sive: Weeks af­ter $213M launch, Tome ac­quires a Berke­ley gene edit­ing start­up for DNA lig­ase tech­nol­o­gy

Last year
Deals

As­traZeneca makes $1B deal for Gra­cell and its cell ther­a­pies, adding to Chi­na ties

Last year
Deals
China

J&J buys eye dis­ease gene ther­a­py from MeiraGTx, giv­ing the biotech the cash in­fu­sion it was seek­ing

Last year
Deals

Bet­ting on pub­lic mar­ket de­mand for more obe­si­ty ther­a­pies, Fractyl Health files for IPO to back gene ther­a­py

Last year
Financing

FDA puts three CARs­gen CAR-T ther­a­pies on clin­i­cal hold, in­clud­ing Mod­er­na-part­nered pro­gram

Last year
FDA+
Manufacturing
First page Previous page 10111213141516 Next page Last page
A service from the Financial Times